PE20001362A1 - Polimorfos de telmisartan y procedimiento para su preparacion - Google Patents
Polimorfos de telmisartan y procedimiento para su preparacionInfo
- Publication number
- PE20001362A1 PE20001362A1 PE1999001284A PE00128499A PE20001362A1 PE 20001362 A1 PE20001362 A1 PE 20001362A1 PE 1999001284 A PE1999001284 A PE 1999001284A PE 00128499 A PE00128499 A PE 00128499A PE 20001362 A1 PE20001362 A1 PE 20001362A1
- Authority
- PE
- Peru
- Prior art keywords
- telmisartran
- procedure
- preparation
- refers
- organic solvent
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 title 2
- 239000005537 C09CA07 - Telmisartan Substances 0.000 title 1
- 229960005187 telmisartan Drugs 0.000 title 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 abstract 3
- -1 CARBOXYL ACID ESTERS Chemical compound 0.000 abstract 2
- 239000003960 organic solvent Substances 0.000 abstract 2
- 229940123413 Angiotensin II antagonist Drugs 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020852 Hypertonia Diseases 0.000 abstract 1
- XLYOFNOQVPJJNP-PWCQTSIFSA-N Tritiated water Chemical compound [3H]O[3H] XLYOFNOQVPJJNP-PWCQTSIFSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 abstract 1
- 238000005119 centrifugation Methods 0.000 abstract 1
- 238000000113 differential scanning calorimetry Methods 0.000 abstract 1
- 238000004821 distillation Methods 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 235000019253 formic acid Nutrition 0.000 abstract 1
- 150000002576 ketones Chemical class 0.000 abstract 1
- 238000002844 melting Methods 0.000 abstract 1
- 230000008018 melting Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 238000002076 thermal analysis method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A UNA MODIFICACION CRISTALINA B POLIMORFA DEL 4`-[2-n-PROPIL-4-METIL-6-(1-METILBENCIMIDAZOL-2-IL)BENCIMIDAZOL-1-ILMETIL]BIFENIL-2-CARBOXILICO (TELMISARTRAN) DE FORMULA I CARACTERIZADA POR UN MAXIMO ENDOTERMICO O PUNTO DE FUSION A 183 +/- 2°C EN EL ANALISIS TERMICO MEDIANTE CALORIMETRIA DE BARRIDO DIFERENCIAL (CBD). TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION DE TELMISARTRAN QUE COMPRENDE a)EL TELMISARTRAN SE RECOGE EN UNA MEZCLA DE DISOLVENTES COMPUESTO POR AGUA, ACIDO FORMICO, DISOLVENTE ORGANICO COMO ESTERES DE ACIDO CARBOXILICOS, CETONAS, ETERES; SE CALIENTA Y FILTRA; b)EL DISOLVENTE ORGANICO SE SEPARA POR DESTILACION; c)LA FORMA B DE TELMISARTRAN SE PRECIPITA DE LA SOLUCION REMANENTE MEDIANTE LA ADICION DE UNA BASE; d)EL PRODUCTO PRECIPITADO SE SEPARA POR CENTRIFUGACION, SE LAVA Y SECA. EL TELMISARTRAN ES UN ANTAGONISTA DE ANGIOTENSINA II POR LO QUE ES UTIL EN EL TRATAMIENTO DE HIPERTONIA E INSUFICIENCIA CARDIACA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19901921A DE19901921C2 (de) | 1999-01-19 | 1999-01-19 | Polymorphe von Telmisartan, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung eines Arzneimittels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20001362A1 true PE20001362A1 (es) | 2000-12-15 |
Family
ID=7894715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1999001284A PE20001362A1 (es) | 1999-01-19 | 1999-12-17 | Polimorfos de telmisartan y procedimiento para su preparacion |
Country Status (36)
| Country | Link |
|---|---|
| EP (1) | EP1144386B1 (es) |
| JP (1) | JP4700813B2 (es) |
| KR (1) | KR100658959B1 (es) |
| CN (1) | CN1144790C (es) |
| AR (1) | AR035475A1 (es) |
| AT (1) | ATE252564T1 (es) |
| AU (1) | AU765081B2 (es) |
| BG (1) | BG65027B1 (es) |
| BR (1) | BR0007584A (es) |
| CA (1) | CA2352436C (es) |
| CO (1) | CO5150238A1 (es) |
| CZ (1) | CZ297412B6 (es) |
| DE (2) | DE19901921C2 (es) |
| DK (1) | DK1144386T3 (es) |
| EA (1) | EA003065B1 (es) |
| EE (1) | EE04344B1 (es) |
| ES (1) | ES2208265T3 (es) |
| HK (1) | HK1041485B (es) |
| HR (1) | HRP20010514B1 (es) |
| HU (1) | HU227401B1 (es) |
| IL (2) | IL143634A0 (es) |
| MY (1) | MY122755A (es) |
| NO (1) | NO319823B1 (es) |
| NZ (1) | NZ513528A (es) |
| PE (1) | PE20001362A1 (es) |
| PL (1) | PL211829B1 (es) |
| PT (1) | PT1144386E (es) |
| RS (1) | RS50044B (es) |
| SA (1) | SA99200838B1 (es) |
| SK (1) | SK285429B6 (es) |
| TR (1) | TR200102074T2 (es) |
| TW (1) | TWI280241B (es) |
| UA (1) | UA56358C2 (es) |
| UY (1) | UY25980A1 (es) |
| WO (1) | WO2000043370A1 (es) |
| ZA (1) | ZA200104771B (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10153737A1 (de) * | 2001-10-31 | 2003-05-28 | Boehringer Ingelheim Pharma | Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels |
| US6737432B2 (en) | 2001-10-31 | 2004-05-18 | Boehringer Ingelheim Pharma Kg | Crystalline form of telmisartan sodium |
| ES2298351T5 (es) | 2002-01-16 | 2012-01-26 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | Método para producir un comprimido farmacéutico de dos capas que comprenden telmisartán e hidroclorotiazida. |
| DE10314702A1 (de) | 2003-03-31 | 2004-10-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von Telmisartan |
| GB2414019A (en) * | 2004-05-11 | 2005-11-16 | Cipla Ltd | One-step preparation of telmisartan by condensation and hydrolysis |
| EP1699765A1 (en) | 2004-10-15 | 2006-09-13 | Teva Pharmaceutical Industries Ltd | Process for preparing telmisartan |
| WO2006044754A2 (en) | 2004-10-18 | 2006-04-27 | Dr. Reddy's Laboratories Ltd. | Process for preparing telmisartan |
| US8637078B2 (en) | 2005-11-24 | 2014-01-28 | Boehringer Ingelheim International Gmbh | Bilayer tablet comprising telmisartan and diuretic |
| EP1908469A1 (en) | 2006-10-06 | 2008-04-09 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin II receptor antagonist for the treatment of systemic diseases in cats |
| DE102008059206A1 (de) | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
| CA2761576C (en) | 2009-05-20 | 2017-08-22 | Boehringer Ingelheim Vetmedica Gmbh | Oral suspension comprising telmisartan |
| HRP20130557T1 (en) | 2009-06-19 | 2013-07-31 | Krka Tovarna Zdravil, D.D., Novo Mesto | Process for the preparation of telmisartan |
| EP2277866A1 (en) | 2009-06-22 | 2011-01-26 | Inke, S.A. | Process for preparing telmisartan |
| WO2011002425A2 (en) | 2009-07-02 | 2011-01-06 | Bilgig Mahmut | Pharmaceutical composition increasing solubility and stability |
| EP2448576A2 (en) | 2009-07-02 | 2012-05-09 | Mahmut Bilgic | Solubility enhancing pharmaceutical composition |
| EA025946B1 (ru) | 2010-10-27 | 2017-02-28 | Крка, Товарна Здравил, Д. Д., Ново Место | Многослойная фармацевтическая композиция, содержащая телмисартан и амлодипин |
| ITMI20102416A1 (it) * | 2010-12-27 | 2012-06-28 | Chemelectiva S R L | Intermedio per la preparazione di un principio attivo e processo per la sua preparazione |
| EP2612658A1 (en) | 2012-01-05 | 2013-07-10 | Laboratorios Lesvi, S.L. | Pharmaceutical compositions of 4'-[(1,4'dimethyl-2'-propyl[2,6'-bi-1h-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid and is 6-chloro-3,4-dihydro-2h-1,2,4-benzothiadiazine-7-sulfonamide-1,1-dioxide |
| JP6147546B2 (ja) * | 2013-04-10 | 2017-06-14 | 株式会社トクヤマ | 酢酸が低減されたテルミサルタンａ型結晶の製造方法 |
| EP2979691A1 (en) | 2014-07-30 | 2016-02-03 | Boehringer Ingelheim International GmbH | Oral disintegrating tablet |
| JP6275596B2 (ja) * | 2014-09-03 | 2018-02-07 | 株式会社トクヤマ | テルミサルタンのアンモニウム塩の製造方法 |
| JP5871294B1 (ja) | 2015-02-27 | 2016-03-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 即時放出経口錠剤 |
| KR20170001921A (ko) | 2015-06-26 | 2017-01-05 | 대원제약주식회사 | 안정성이 개선된 텔미사르탄을 함유하는 약제학적 조성물 및 이의 제조방법 |
| KR20170012703A (ko) | 2015-07-22 | 2017-02-03 | 대원제약주식회사 | 텔미사르탄을 함유하는 약제학적 조성물 및 이의 제조방법 |
| EP3463309B1 (en) | 2016-05-30 | 2020-06-17 | Boehringer Ingelheim International GmbH | Fixed dose combination of telmisartan, hydrochlorothiazide and amlodipine |
| KR102044223B1 (ko) * | 2016-09-12 | 2019-11-13 | 성균관대학교산학협력단 | 텔미사르탄을 포함하는 고체 분산체 및 이의 제조방법 |
| CN106749036B (zh) * | 2016-12-21 | 2019-06-21 | 山东大学 | 一种无定型的替米沙坦-庚二酸共晶及其制备方法和应用 |
| CN106749037B (zh) * | 2016-12-21 | 2019-06-21 | 山东大学 | 一种无定型的替米沙坦-戊二酸共晶及其制备方法和应用 |
| NZ759782A (en) | 2017-07-07 | 2023-06-30 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin ii receptor antagonist for the prevention or treatment of systemic diseases in cats |
| CN109851562A (zh) * | 2019-01-30 | 2019-06-07 | 浙江省食品药品检验研究院 | 一种替米沙坦晶体及其制备方法 |
| EP4373474A1 (en) | 2021-07-22 | 2024-05-29 | KRKA, D.D., Novo Mesto | Bilayer tablet comprising telmisartan and indapamide |
| TW202508455A (zh) | 2023-05-24 | 2025-03-01 | 德商百靈佳殷格翰維美迪加股份有限公司 | 包含一或多種sglt-2抑制劑及替米沙坦(telmisartan)之非人類哺乳動物之腎臟疾病及/或高血壓之組合治療及/或預防 |
| WO2024240632A1 (en) | 2023-05-24 | 2024-11-28 | Boehringer Ingelheim Vetmedica Gmbh | Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan |
| US20250195525A1 (en) | 2023-12-15 | 2025-06-19 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin ii receptor antagonist for the prevention of systemic diseases in cats |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI9210098B (sl) * | 1991-02-06 | 2000-06-30 | Dr. Karl Thomae | Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo |
| US5139114A (en) * | 1991-03-18 | 1992-08-18 | Abex Corporation | Visible brake block wear indicator |
-
1999
- 1999-01-19 DE DE19901921A patent/DE19901921C2/de not_active Expired - Fee Related
- 1999-12-17 PE PE1999001284A patent/PE20001362A1/es not_active Application Discontinuation
- 1999-12-26 SA SA99200838A patent/SA99200838B1/ar unknown
-
2000
- 2000-01-07 HR HR20010514A patent/HRP20010514B1/xx not_active IP Right Cessation
- 2000-01-07 SK SK1020-2001A patent/SK285429B6/sk not_active IP Right Cessation
- 2000-01-07 PT PT00901510T patent/PT1144386E/pt unknown
- 2000-01-07 HK HK02103090.1A patent/HK1041485B/zh not_active IP Right Cessation
- 2000-01-07 DE DE50004150T patent/DE50004150D1/de not_active Expired - Lifetime
- 2000-01-07 BR BR0007584-1A patent/BR0007584A/pt not_active Application Discontinuation
- 2000-01-07 NZ NZ513528A patent/NZ513528A/en not_active IP Right Cessation
- 2000-01-07 KR KR1020017008958A patent/KR100658959B1/ko not_active Expired - Fee Related
- 2000-01-07 CN CNB00802880XA patent/CN1144790C/zh not_active Expired - Fee Related
- 2000-01-07 EA EA200100730A patent/EA003065B1/ru not_active IP Right Cessation
- 2000-01-07 IL IL14363400A patent/IL143634A0/xx active IP Right Grant
- 2000-01-07 ES ES00901510T patent/ES2208265T3/es not_active Expired - Lifetime
- 2000-01-07 EE EEP200100375A patent/EE04344B1/xx not_active IP Right Cessation
- 2000-01-07 PL PL349425A patent/PL211829B1/pl unknown
- 2000-01-07 AU AU22881/00A patent/AU765081B2/en not_active Ceased
- 2000-01-07 JP JP2000594786A patent/JP4700813B2/ja not_active Expired - Lifetime
- 2000-01-07 DK DK00901510T patent/DK1144386T3/da active
- 2000-01-07 CA CA2352436A patent/CA2352436C/en not_active Expired - Fee Related
- 2000-01-07 RS YUP-511/01A patent/RS50044B/sr unknown
- 2000-01-07 HU HU0105148A patent/HU227401B1/hu not_active IP Right Cessation
- 2000-01-07 WO PCT/EP2000/000065 patent/WO2000043370A1/de not_active Ceased
- 2000-01-07 EP EP00901510A patent/EP1144386B1/de not_active Expired - Lifetime
- 2000-01-07 AT AT00901510T patent/ATE252564T1/de active
- 2000-01-07 CZ CZ20012634A patent/CZ297412B6/cs not_active IP Right Cessation
- 2000-01-07 TR TR2001/02074T patent/TR200102074T2/xx unknown
- 2000-01-17 TW TW089100637A patent/TWI280241B/zh not_active IP Right Cessation
- 2000-01-17 MY MYPI20000130A patent/MY122755A/en unknown
- 2000-01-18 UY UY25980A patent/UY25980A1/es not_active Application Discontinuation
- 2000-01-18 CO CO00002435A patent/CO5150238A1/es unknown
- 2000-01-19 AR ARP000100241A patent/AR035475A1/es active IP Right Grant
- 2000-07-01 UA UA2001085811A patent/UA56358C2/uk unknown
-
2001
- 2001-06-07 IL IL143634A patent/IL143634A/en not_active IP Right Cessation
- 2001-06-12 ZA ZA200104771A patent/ZA200104771B/en unknown
- 2001-06-27 BG BG105654A patent/BG65027B1/bg unknown
- 2001-07-18 NO NO20013560A patent/NO319823B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20001362A1 (es) | Polimorfos de telmisartan y procedimiento para su preparacion | |
| Bahekar et al. | Synthesis and antidiabetic activity of 2, 5-disubstituted-3-imidazol-2-yl-pyrrolo [2, 3-b] pyridines and thieno [2, 3-b] pyridines | |
| KR102786409B1 (ko) | 개선된 인도시아닌 그린의 제조방법 | |
| DE69113379T2 (de) | 3-Aryl-4(3H)chinazolinone als CCK Antagonisten und diese enthaltende pharmazeutische Zusammensetzungen. | |
| EA200100042A1 (ru) | Бензимидазолы, их получение и их применение в качестве лекарственных средств | |
| AR072557A1 (es) | Proceso para preparar composiciones de medicamentos que contienen dabigatran | |
| RS58594B1 (sr) | Jedinjenja dimetilbenzoeve kiseline | |
| NO20021336D0 (no) | Gjenvinningsprosess av fluktige forbindelser fra faststoffer i en vandig opplösning | |
| PT1204650E (pt) | Compostos de 2-arilbenzazole substituido e sua utilizacao como agentes antitumorais. | |
| RS56615B1 (sr) | Derivati fenoksietil cikličnih amina i njihova aktivnost kao modulatora ep4 receptora | |
| EA200970797A1 (ru) | Способ получения продукта на основе фекалий животных, а также установка для получения продукта, в частности продукта-удобрения | |
| AR013051A1 (es) | Aislacion y purificacion de esteroles a partir de fracciones neutras de resina de tallol mediante cristalizacion de decantacion unica | |
| ATE406362T1 (de) | Verfahren zur herstellung von optisch aktiven derivaten von 2-(2- pyridylmethylsulfinyl)benzimidazol über einen einschlusskomplex mit 1,1'-binaphthalin-2, 2'- diol | |
| JP4898446B2 (ja) | 選択的なアンドロゲン受容体モジュレーター（ｓａｒｍｓ）としてのチアゾリン誘導体 | |
| NO20090748L (no) | Fremgangsmate for rensing av montelukast | |
| JP2020109132A (ja) | ミネラルコルチコイド受容体拮抗剤としての化合物の結晶形及びその調製方法 | |
| RU2481344C2 (ru) | Замещенные (оксазолидинон-5-ил-метил)-2-тиофен-карбоксамиды и их применение в сфере свертывания крови | |
| Goyal et al. | Synthesis and pharmacological evaluation of some novel imidazole derivatives for their potential anti-hypertensive activity | |
| CN103232398A (zh) | 一种瑞舒伐他汀氨基酸盐及其制备方法和应用 | |
| PE20020543A1 (es) | Derivados de la indolilpiperidina como agentes antihistaminicos y antialergicos | |
| PE20081664A1 (es) | Derivados de azabicicloalcano, su preparacion y su aplicacion en terapeutica | |
| Zhang et al. | Synthesis and biological evaluation of (R)-N-(diarylmethylthio/sulfinyl) ethyl/propyl-piperidine-3-carboxylic acid hydrochlorides as novel GABA uptake inhibitors | |
| CN106496099A (zh) | 2‑[(2r,6s)‑6‑[(2s)‑2‑羟基‑2‑苯乙基]‑1‑甲基哌啶]‑1‑苯乙酮的合成方法 | |
| DE4341663A1 (de) | Anellierte 2-Oxopiperazine, ihre Herstellung und Verwendung | |
| DE3878700T2 (de) | Verfahren zur herstellung von thiazolobenzimidazolen und zwischenprodukte. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |